TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18433672
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.2% ropivacaine 10 mL/h (group R, n = 22)
Study: 18433672
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.9% NaCl 10 mL/h (group S, n = 22)
Study: 14556808
Drug: Peritoneal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal fluid IL-18 levels in women with superficial peritoneal implants
Study: 14556808
Drug: Peritoneal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal fluid IL-18 levels in women with deep peritoneal implants
Study: 11073017
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2 g elemental calcium daily)
Study: 11073017
Drug: Fibre supplementation
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplementation (3.5 g ispaghula husk)
Study: 8398526
Drug: lumbar extradural
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lumbar extradural analgesia using 0.5% bupivacaine 1 mg kg‐1 plus morphine 50 micrograms kg‐1
Study: 8398526
Drug: morphine 100
Normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 100 micrograms kg‐1 i.m.
Study: 8398526
Drug: subpubic block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: subpubic block using 0.5% bupivacaine 0.5 mg kg‐1 for each side
Study: 24991030
Drug: Noninvasive repetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive repetitive transorbital alternating current stimulation (rtACS; 10 days, 40 minutes daily; n = 7)
Study: 22910840
Drug: Second line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second line therapy (platinum combination, n = 313, 24.5%)
Study: 22910840
Drug: Third line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third line therapy (topotecan, n = 118, 23.6%)
Study: 22910840
Drug: Fourth line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth line therapy
Study: 22910840
Drug: Fifth line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifth line therapy
Study: 15976235
Drug: Carbamazepine 100
Normalized name: carbamazepine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 100 mg
Study: 9085622
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg IV after 500 ml of enteral nutrition
Study: 9085622
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg IV after 500 ml of enteral nutrition
Study: 26864124
Drug: Liraglutide (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (not specified dosage or duration)
Study: 26864124
Drug: Treatment intensity
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment intensity (insulin, statins, oral antihypertensive drugs)
Study: 19827461
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (CD), 5.5 +/- 0.3 g/d of L-arginine
Study: 19827461
Drug: Diet 2
Normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 2 (same as CD but including an oral supplement of 15 g/d), 20.5 +/- 0.3 g/d of L-arginine
Study: 9492093
Drug: Free fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free fraction of L-tryptophan in plasma
Study: 9492093
Drug: L-tryptophan and
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan and serotonin synthesis
Study: 9492093
Drug: Free fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free fraction of plasma L-tryptophan
Study: 3266541
Drug: Sodium metabisulfite
Normalized name: Sodium Metabisulfite
DrugBank: Sodium metabisulfite (DB15842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium metabisulfite solutions (0.5, 1, 10, 25, 50 mg, 100 mg, 200 mg)
Study: 26092062
Drug: Weekly teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly teriparatide
Study: 11025425
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy (NHT) prior to radical prostatectomy
Study: 11025425
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy (NHT) prior to radiation therapy
Study: 9309996
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 40 ppm
Study: 3770017
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and diuretic
Study: 3770017
Drug: Sotalol and
Normalized name: sotalol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol and diuretic
Study: 26914585
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (H1N1 strain)
Study: 26914585
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (H3N2 strain)
Study: 26914585
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (B strain)
Study: 22640372
Drug: Osteo-cise intervention
Normalized name: Osteo-Poretical
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osteo-cise intervention (multi-modal exercise program with high velocity progressive resistance training, moderate impact weight-bearing exercise, and high challenging balance exercises performed three times weekly)
Study: 20119672
Drug: Intraoperative periarticular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative periarticular multimodal drug injections (PMDI)
Study: 12095018
Drug: Meperidine (rescue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (rescue medication)
Study: 8919987
Drug: morphine 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.50 mg/ml + ketorolac 1.50 mg/ml (Group 2)
Study: 8919987
Drug: morphine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.75 mg/ml + ketorolac 0.75 mg/ml (Group 1)
Study: 8919987
Drug: morphine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.25 mg/ml + ketorolac 1.50 mg/ml (Group 3)
Study: 400713
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (iv)
Study: 400713
Drug: Intramuscular insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular insulin (im)
Study: 400713
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (sc)
Study: 31607720
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (NSS) applied to the wound after tooth extraction
Study: 18694136
Drug: Non-interruptive alert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-interruptive alert within electronic medical record prompting lab orders with new prescriptions
Study: 16821203
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (transsphenoidal surgery)
Study: 16821203
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (Sandostatin LAR, 20 mg im, monthly)
Study: 10350382
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of meropenem: 2 g iv loading dose followed by 3 g continuous infusion over 24 h
Study: 10350382
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration (IA) of meropenem: 2 g iv every 8 h
Study: 8596317
Drug: Subcutaneous dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days)
Study: 8596317
Drug: Subcutaneous dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dalteparin (Fragmin)
Study: 1959860
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glucagon therapy (30 U insulin and 3 mg glucagon in 250 ml 5% dextrose over 12 hr each day for 3 wk)
Study: 1959860
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical regime to insulin and glucagon)
Study: 786190
Drug: Steroid-treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-treated group (DMP + MPS)
Study: 31755948
Drug: Rifampin therapy
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin therapy for at least 14 days within 90 days of diagnosis
Study: 31755948
Drug: No rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rifampin therapy
Study: 26477692
Drug: ETABJ (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETABJ (matched etanercept and 50 ml blueberry juice daily)
Study: 26477692
Drug: ETA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETA (50 mg of etanercept twice weekly)
Study: 17189962
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch plus venlafaxine
Study: 15371578
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a monotherapy (180 microg once weekly)
Study: 15371578
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a plus lamivudine (100 mg daily)
Study: 15371578
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy (100 mg daily)
Study: 11773925
Drug: Angina clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angina clinic (optimized antianginal medications)
Study: 9842823
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 5 microg/kg 90 min before spinal anesthesia
Study: 8080740
Drug: Intact A5B7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact A5B7 IgG1 mouse monoclonal antibody (MAb) to CEA
Study: 8080740
Drug: F(ab')2 fragment
Normalized name: Anti-Shiga toxin hyperimmune equine immunoglobulin F(ab')2 fragment
Approvals — FDA: no, EMA: no, PMDA: no
Description: F(ab')2 fragment of the same antibody
Study: 2757960
Drug: Stage C
Normalized name: TITANIUM DIOXIDE 0.234 g in 100 g TOPICAL STICK [ALL ABOUT SOO SUN STAGE COOLSTICK SPF50 PA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage C treatment
Study: 2757960
Drug: Age and
Normalized name: wound drainage and fistula management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age and response to treatment
Study: 862429
Drug: Synemol cream
Normalized name: fluocinolone acetonide Topical Cream [Synemol]
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synemol cream (0.025%)
Study: 862429
Drug: Diproson cream
Normalized name: Alclometasone Dipropionate
DrugBank: Alclometasone (DB00240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diproson cream (0.05%)
Study: 862429
Drug: Aristocort‐A cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aristocort‐A cream (0.5%)
Study: 862429
Drug: Valisone cream
Normalized name: Valine
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valisone cream (0.1%)
Study: 31675420
Drug: Combined Oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Oral Contraceptive Pills (COCPs)
Study: 30992659
Drug: KM-819 (FAS-associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: KM-819 (FAS-associated factor 1 inhibitor)
Study: 27755057
Drug: Programmed Intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed Intermittent Epidural Bolus (PIEB) of 10 mL of bupivacaine 0.0625% with fentanyl 2 μg/mL
Study: 23800977
Drug: perindopril 10
Normalized name: amlodipine-perindopril 10 mg-14 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril 10 mg/day
Study: 21711255
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment from day 1 without detoxification
Study: 21711255
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient detoxification program without preventive treatment from day 1
Study: 31307393
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment
Study: 18353314
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg reteplase in 300 mL Ringer's lactate
Study: 18353314
Drug: 300 mL
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mL Ringer's lactate only
Study: 16442897
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) infusion during primary PCI
Study: 12562449
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily for 4 weeks
Study: 8490078
Drug: Placebo, H2-antagonists,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, H2-antagonists, or omeprazole
Study: 29344879
Drug: Placebo 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 100 mg/day
Study: 27956407
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment for 12 weeks
Study: 17043834
Drug: 10% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% urea lacquer applied once daily for 28 days
Study: 17043834
Drug: 10% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% urea lacquer applied twice daily for 28 days
Study: 12393429
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment with fludarabine and rituximab
Study: 12393429
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with fludarabine followed by rituximab
Study: 10513457
Drug: Fananserin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fananserin (600 mg/day) with slow titration (100 mg increases every 3 days)
Study: 10513457
Drug: Fananserin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fananserin (600 mg/day) with rapid titration (200 mg increases every 3 days)
Study: 10513457
Drug: Fananserin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fananserin (600 mg/day) with intermediate titration (100 mg increases every 2 days)
Study: 10513457
Drug: Fananserin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fananserin (multiple doses)
Study: 2898027
Drug: Cholestyramine resin
Normalized name: Cholestyramine Resin
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholestyramine resin (12 g, twice a day)
Study: 2898027
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg, twice a day)
Study: 2898027
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg, twice a day)
Study: 30060902
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (CLA): clarithromycin 500mg, lansoprazole 30mg, amoxicillin 1g, all bid for 10 days
Study: 30060902
Drug: Levofloxacin-based therapy
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based therapy (PLA): pantoprazole 80mg, levofloxacin 500mg, azithromycin 500mg, all od for 10 days
Study: 28588166
Drug: Local steroid
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroid injection (triamcinolone acetate)
Study: 25577713
Drug: Bupivacaine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.3 mL per side, intranasally)
Study: 25577713
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (0.3 mL per side, intranasally)
Study: 17116021
Drug: RWJ-333369 (100-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-333369 (100-750 mg)
Study: 17116021
Drug: RWJ-333369 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-333369 (750 mg)
Study: 17116021
Drug: RWJ-333369 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-333369 (750 mg) under fed conditions
Study: 9209786
Drug: Clarithromycin (CAM)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (CAM) 400 mg/day, orally
Study: 9209786
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (non-CAM)
Study: 7957544
Drug: Umespirone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umespirone 20 mg
Study: 7957544
Drug: Umespirone 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umespirone 80 mg
Study: 3624110
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg single oral dose)
Study: 3624110
Drug: Ampicillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (2 g single oral dose and 500 mg four times per day for five days)
Study: 21782948
Drug: Sub-antimicrobial-dose doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sub-antimicrobial-dose doxycycline (SDD) for 3 months
Study: 21782948
Drug: Antimicrobial-dose doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimicrobial-dose doxycycline (ADD) for 2 weeks
Study: 15131558
Drug: Oral rosiglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rosiglitazone for 6 months
Study: 15131558
Drug: Oral rosiglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rosiglitazone
Study: 11296803
Drug: Standardized exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized exercises (SE) and slider board (SB) therapy
Study: 9310811
Drug: Apnoea tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apnoea tests without CO2 augmentation (group A)
Study: 9310811
Drug: Apnoea tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apnoea tests with CO2 augmentation (group B)
Study: 8317029
Drug: Buprenorphine (priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (priming dose i.m. at wound closure, sublingual buprenorphine every eight hours)
Study: 8317029
Drug: Morphine (priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (priming dose i.m. at wound closure, sublingual placebo every eight hours)
Study: 2873106
Drug: Extempore combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extempore combination of salbutamol syrup plus 30‐mg oxatomide tablets
Study: 2873106
Drug: 30‐mg oxatomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐mg oxatomide tablets alone
Study: 31511891
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment in rHEMI+ patients
Study: 31511891
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment in rHEMI- patients
Study: 31511891
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment for rHEMI+ vs rHEMI- patients
Study: 23701262
Drug: GSK256073 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256073 5 mg BID
Study: 23701262
Drug: GSK256073 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256073 10 mg QD
Study: 23701262
Drug: GSK256073 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256073 25 mg BID
Study: 23701262
Drug: GSK256073 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256073 50 mg QD
Study: 11174230
Drug: Sublingual hyoscyamine
Normalized name: hyoscyamine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual hyoscyamine sulfate (0.125 mg) with ketorolac tromethamine (30 mg IV)
Study: 11174230
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with ketorolac tromethamine (30 mg IV)
Study: 9670686
Drug: Laferon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laferon therapy as part of complex treatment schemes
Study: 31437865
Drug: Tegoprazan 400
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 400 mg
Study: 31437865
Drug: Tegoprazan 100
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 100 mg (multiple doses)
Study: 31437865
Drug: Tegoprazan 200
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 200 mg (multiple doses)
Study: 31437865
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg (control)
Study: 26498603
Drug: 6-h magnesium
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-h magnesium sulfate therapy (4 g loading dose followed by 1 gm/h infusion for 6 h)
Study: 26498603
Drug: 24-h conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h conventional magnesium sulfate therapy (4 g loading dose followed by 1 gm/h infusion for 24 h)